Nisa Investment Advisors LLC Boosts Stock Holdings in Insulet Corporation (NASDAQ:PODD)

Nisa Investment Advisors LLC grew its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 69.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,445 shares of the medical instruments supplier's stock after purchasing an additional 3,057 shares during the quarter. Nisa Investment Advisors LLC's holdings in Insulet were worth $1,955,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Itau Unibanco Holding S.A. bought a new position in Insulet during the fourth quarter valued at approximately $42,000. Golden State Wealth Management LLC boosted its stake in shares of Insulet by 553.1% in the 1st quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock valued at $55,000 after purchasing an additional 177 shares in the last quarter. Assetmark Inc. grew its holdings in shares of Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares during the last quarter. Coppell Advisory Solutions LLC boosted its position in Insulet by 135.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock valued at $74,000 after buying an additional 162 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its stake in shares of Insulet by 23.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock valued at $82,000 after buying an additional 59 shares during the last quarter.

Insider Activity at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president directly owned 23,180 shares in the company, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.39% of the company's stock.

Insulet Trading Up 0.9%

Shares of NASDAQ:PODD traded up $2.69 during trading on Monday, reaching $292.01. The company's stock had a trading volume of 605,791 shares, compared to its average volume of 793,154. The stock has a market capitalization of $20.55 billion, a PE ratio of 52.52, a price-to-earnings-growth ratio of 2.58 and a beta of 1.35. Insulet Corporation has a 12 month low of $173.00 and a 12 month high of $329.33. The company has a current ratio of 4.47, a quick ratio of 3.63 and a debt-to-equity ratio of 1.21. The firm's 50 day simple moving average is $307.29 and its two-hundred day simple moving average is $280.25.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The firm had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. During the same quarter last year, the business earned $0.73 EPS. The business's revenue was up 28.8% on a year-over-year basis. On average, research analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on PODD shares. Truist Financial assumed coverage on Insulet in a research report on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective for the company. Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Barclays raised their price target on shares of Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Wolfe Research raised shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective for the company in a research note on Tuesday, May 13th. Finally, Citigroup reiterated a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $321.00.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.